The most excited advance mentioned above has been reported lately that the compound with dual PARP and EZH2 inhibitors, showed good inhibitory activity against PARP-1 and EZH2 and good inhibitory effects on multiple type of triple-negative breast cancer (TNBC) cell lines with wild-type BRCA, with a slight harm on normal cells, suggesting possible safety of the combined strategy in clinical context (Wang et al., 2021). Here, PARP1 is linked to triple-negative breast carcinoma.